Sherratt-Mayhew, SamNicolson, Phillip L R2024-09-272024-09-272024-06-16Sherratt-Mayhew S, Nicolson PLR. Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report. EJHaem. 2024 Jun 16;5(4):825-828. doi: 10.1002/jha2.937.2688-614610.1002/jha2.93739157612http://hdl.handle.net/20.500.14200/5955Pure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune-related adverse event secondary to immune checkpoint inhibitor (ICI) therapy is rare. Steroids are usually used first line to treat ICI-induced PRCA. Here, we report a case of ICI-induced PRCA with no response to steroids but where intravenous (IV) immunoglobulin was successfully used second line. ICI therapy was reinitiated following PRCA resolution. PRCA recurrence did not occur.en© 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.HaematologyMicrobiology. ImmunologyReport